Search
Presentations 2006

 

The 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006

Poster Presentations

1 Comparison of single and boosted-protease-inhibitor (PI) versus non-nucleoside reverse transcriptase inhibitor (NNRTI) containing regimens in previously antiretroviral naïve patients. A Mocroft, O Kirk, A Horban, N CLumeck, HJ Stellbrink, A d´Arminio, K Zilmer, J Gatell, AN Phillips, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 138 kb 

2 Abacavir hypersensitivity reaction in EuroSIDA. W Bannister, N Friis-Møller, A Mocroft, JP Viard, J van Lunzen, O Kirk, P Garglianos, D Banhegyi, A Chiesi, J Lundgren for the EuroSIDA study group.
Poster as pdf file 673 kb

13th Conference o­n Retroviruses and Opportunistic Infections, Denver, February 2006

Posters

1 Mutation at reverse transcriptase codon 214 is antagonist to thymidine analogue mutations type 2 profiles and predicts virological response to thymidine analogue-containing cART regimens only if TAM type 1 profiles concomitantly detected. A Cozzi-Lepri, L Ruiz, F Ceccherini-Silberstein, A Mocroft, A Phillips, J Gatell, B Ledergerber, P Reiss, B Clotet, JD Lundgren and the EuroSIDA Study group.
Poster  as pdf file 966 KB

2 Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4 cell counts in the EuroSIDA study. D Podlekareva, U Dragsted, A Mocroft, B Ledergerber, M Beniowski, A Lazzarin, J Weber, N Clumeck, A Phillips, JD Lundgren and the EuroSIDA Study group.
Poster as pdf file 76 KB

The XVI International AIDS Conference, Toronto, August 2006

Oral Presentation

1 Risk of discontinuation of nevirapine due to toxicitites in antiretroviral naive and experienced patients with high and low CD4 counts. A Mocroft, J Rockstroh, J Gasiorowski, F Antunes, G Panos, A d´Arminio Monforte, A Rakhmanova,, AN Phillips, JD Lundgren for the EuroSIDA study group.
Slides as pdf file 153 KB

Posters

1 The ability of four genotypic resistance algorithmis for predicting HIV-RNA responses 4-24 weeks after initiating a boosted PI-containing regimen. Z Fox, J Kjær, AN Phillips, L Ruiz, B Clotet, S Staszewski, C Holkmann Olsen, A Horban, B Ledergerber, JD Lundgren for the EuroSIDA study group.
Poster as pdf file  137 KB

2 Genotypic resistance profile before initiation of cART and association with virological and clinical outcome in EuroSIDA. WP Bannister, AN Phillips, B Clotet, P Reiss, B Ledergerber, A Lazzarin, C Katlama, A Cozzi-Lepri, L Ruiz, JD Lundgren for the EuroSIDA study group.
Poster as pdf file 85 KB

3 Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score. A Mocroft, B Ledergerber, K Zilmer, O Kirk, B Hirschel, JP Viard, P Reiss, P Francioli, A Lazzarin, L Machala, AN Phillips, JD Lundgren for the EuroSIDA study and the Swiss HIV Cohort study.
Poster as pdf file 759 KB